HN3Q Stock Overview
Through its subsidiaries, operates as a biotechnology company worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Nova Mentis Life Science Corp. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.005 |
| 52 Week High | CA$0.065 |
| 52 Week Low | CA$0.0005 |
| Beta | 0.68 |
| 1 Month Change | 0% |
| 3 Month Change | 900.00% |
| 1 Year Change | -78.26% |
| 3 Year Change | -90.00% |
| 5 Year Change | -98.44% |
| Change since IPO | -99.79% |
Recent News & Updates
Recent updates
Shareholder Returns
| HN3Q | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | 0.6% | -0.4% |
| 1Y | -78.3% | -25.6% | 4.2% |
Return vs Industry: HN3Q underperformed the German Biotechs industry which returned -23.7% over the past year.
Return vs Market: HN3Q underperformed the German Market which returned 5.4% over the past year.
Price Volatility
| HN3Q volatility | |
|---|---|
| HN3Q Average Weekly Movement | 279.4% |
| Biotechs Industry Average Movement | 5.1% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in DE Market | 10.4% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: HN3Q's share price has been volatile over the past 3 months.
Volatility Over Time: HN3Q's weekly volatility has increased from 253% to 279% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | n/a | Will Rascan | www.novamentis.ca |
Nova Mentis Life Science Corp., through its subsidiaries, operates as a biotechnology company worldwide. It engages in developing diagnostics and psilocybin-based therapeutics for the treatment of neuroinflammatory disorders, including autism spectrum disorder and fragile X syndrome. The company was formerly known as Liberty Leaf Holdings Ltd.
Nova Mentis Life Science Corp. Fundamentals Summary
| HN3Q fundamental statistics | |
|---|---|
| Market cap | €1.50m |
| Earnings (TTM) | -€827.48k |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-1.8x
P/E RatioIs HN3Q overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| HN3Q income statement (TTM) | |
|---|---|
| Revenue | CA$0 |
| Cost of Revenue | CA$0 |
| Gross Profit | CA$0 |
| Other Expenses | CA$1.22m |
| Earnings | -CA$1.22m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0083 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did HN3Q perform over the long term?
See historical performance and comparison